- Home
- NMS vs CSBR Comparison
NMS vs CSBR Comparison
Compare NMS & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | CSBR |
|---|---|---|
| Founded | 1993 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 66.7M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NMS | CSBR |
|---|---|---|
| Price | $9.97 | $4.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.2K | 12.5K |
| Earning Date | 01-01-0001 | 09-10-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $9.83 |
| Revenue Next Year | N/A | $8.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $4.59 |
| 52 Week High | $12.50 | $8.31 |
Technical Indicators
Market Signals| Indicator | NMS | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 46.98 |
| Support Level | N/A | $4.71 |
| Resistance Level | $12.48 | $6.31 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.51 | 36.19 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.